Roivant Sciences Ltd’s recently made public that its President & CIO Sukhatme Mayukh unloaded Company’s shares for reported $22.12 million on Dec 31 ’25. In the deal valued at $21.71 per share,1,018,995 shares were sold. As a result of this transaction, Sukhatme Mayukh now holds 20,267,429 shares worth roughly $437.98 million.
Then, Sukhatme Mayukh sold 311,873 shares, generating $6,780,119 in total proceeds. Upon selling the shares at $21.74, the President & CIO now owns 19,273,032 shares.
Before that, Sukhatme Mayukh bought 1,018,995 shares. Roivant Sciences Ltd shares valued at $22,119,828 were divested by the Officer at a price of $21.71 per share.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Tuesday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 1.46% to $21.61. Over the last five days, the stock has lost -0.41%. Roivant Sciences Ltd shares have risen nearly 78.89% since the year began. Nevertheless, the stocks have fallen -0.41% over the past one year. While a 52-week high of $23.47 was reached on 01/02/26, a 52-week low of $8.73 was recorded on 01/05/26.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 21.38, which if violated will result in even more drops to 21.15. On the upside, there is a resistance level at 21.86. A further resistance level may holdings at 22.11.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-12-15, dropping by -5.53 million shares to a total of 17.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 23.05 million shares. There was a decline of -31.56%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
